Immix Biopharma, Inc. (IMMX) has a consensus analyst rating of Buy, based on 4 analysts covering the stock. Of those, 4 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for IMMX is $13.00, representing a +32.0% upside from the current price of $9.85. Price targets range from a low of $12.00 to a high of $14.00.
